Theravance Biopharma Company Profile (NASDAQ:TBPH)

Analyst Ratings

Consensus Ratings for Theravance Biopharma (NASDAQ:TBPH) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $24.33 (4.61% downside)

Analysts' Ratings History for Theravance Biopharma (NASDAQ:TBPH)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016Leerink SwannBoost Price TargetOutperform$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016GuggenheimInitiated CoverageBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Bank of America Corp.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Robert W. BairdReiterated RatingNeutral$17.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Theravance Biopharma (NASDAQ:TBPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q116($0.96)($1.10)$18.69 million$18.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($1.62)($1.23)($280,000.00) million$3.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($1.44)($1.40)$4.24 million$10.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($1.51)($1.42)$4.25 million$7.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2015Q414($1.70)($2.02)$2.01 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q3 14($1.85)($1.72)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014($0.56)($1.83)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Theravance Biopharma (NASDAQ:TBPH)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($1.20)($1.20)($1.20)
Q3 20161($1.05)($1.05)($1.05)
Q4 20161($0.97)($0.97)($0.97)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Theravance Biopharma (NASDAQ:TBPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Theravance Biopharma (NASDAQ:TBPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/14/2016Plc GlaxosmithklineMajor ShareholderBuy1,301,015$23,028,000.00$29,959,773,420,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Plc GlaxosmithklineMajor ShareholderBuy44,574$607,544.00$27,080,666,256.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Burton G MalkielDirectorBuy10,000$12.92$129,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Junning LeeVPBuy9,000$12.90$116,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Renee D GalaCFOBuy10,000$12.18$121,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Rick E WinninghamCEOBuy80,000$11.86$948,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Theravance Biopharma (NASDAQ:TBPH)
DateHeadline
07/29/16 06:55 PMCommit To Buy Theravance Biopharma At $20, Earn 14.2% Annualized Using Options
07/22/16 07:16 AMTheravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : July 22, 2016 -
07/20/16 09:38 AMTBPH-Trek-6450-Clinical-Trial-Press-Release-Final_102715
07/07/16 06:46 PMTheravance Biopharma Announces New Employment Inducement Awards
07/06/16 03:21 PMTheravance Biopharma to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - f3dfc842-d9ef-4785-ad5a-cc3d7c4e487c.pdf July 6, 2016 DUBLIN, IRELAND -- (Marketwired) -- 07/06/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Brett Haumann, Senior Vice President, ...
06/21/16 09:26 AMGSK FULFILS Goals, CDXC Sinks On Short Seller Report, LPTN Up On Defense Grant
06/20/16 06:42 PMTheravance Biopharma Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva - [Marketwired] - Theravance Biopharma, Inc. today announced that GlaxoSmithKline plc and Innoviva, Inc. have disclosed positive top-line results from the pivotal Phase 3 FULFIL study of the Closed Triple in patients with ...
06/20/16 08:10 AMNew Data Shows Potent in vitro Activity of VIBATIV(R) (telavancin) Against Difficult-to-Treat Clinical Pathogens, Including MRSA
06/14/16 07:02 AMTHERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/13/16 07:29 AMTheravance Biopharma to Present New Data Highlighting Potent in vitro Activity of VIBATIV(R) (telavancin) Against Difficult-to-Treat, Clinical Pathogens, Including MRSA, at ASM Microbe 2016 Conference - [at noodls] - ff50b3ab-cbb4-46e5-a6f5-d29088d7bb39.pdf June 13, 2016 Study Findings Highlight Greater in vitro Potency for VIBATIV Compared to Other Well-Known Antibiotics Such as Vancomycin, Daptomycin and Linezolid ...
06/10/16 09:47 AMTheravance Biopharma (TBPH) Says TD-1473 Well Tolerated in Phase 1 Clinical Trial
06/09/16 09:48 AMTheravance Biopharma Signs Licensing Deal with Takeda
06/09/16 09:48 AMTheravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor
06/08/16 07:29 AMTakeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders - [PR Newswire] - TD-8954 is being developed for the short-term use with EFI to achieve early nutritional adequacy in critically ill patients at high nutritional risk, an indication for which the compound received U.S. Food and Drug Administration (FDA) Fast Track Designation. Theravance Biopharma has most recently completed a study evaluating the safety, tolerability and pharmacodynamics of a single dose of the compound administered intravenously compared to metoclopramide in critically ill patients with EFI. "The addition of TD-8954 to our portfolio highlights Takeda's commitment to the development of treatments to improve the health of patients with gastroenterological disorders," said Asit Parikh, M.D., Ph.D., Head, Gastroenterology Therapeutic Area Unit, Takeda. "As a leader in gastroenterology, Takeda has a history of bringing innovative treatments to patients where there is significant unmet need.
06/03/16 08:40 AMGlaxo/Innoviva Expedite Closed Triple Combination NDA Filing -
06/02/16 06:35 PMTheravance Biopharma Highlights Acceleration of Timeline for Filing U.S. New Drug Application for the Closed Triple by GlaxoSmithKline and Innoviva - [at noodls] - 3457ff23-eb92-4265-a021-fc95f71fff85.pdf June 2, 2016 Theravance Biopharma Entitled to Receive 85% Economic Interest in Royalties Paid by GSK as Part of Agreement With Innoviva DUBLIN, IRELAND -- (Marketwired) ...
06/02/16 09:55 AMNo Objection To EverSweet, CTRV Awaits Data In Q4, Two Down, One To Go For DERM - RPRX closed Wednesday's trading at $1.69, down 8.65%. In after hours, the stock was up 15.98% to $2.01. Theravance Biopharma Inc. (TBPH) has completed enrollment in all three studies of its phase III program of Revefenacin for the treatment of chronic ...
06/01/16 07:33 AMTheravance Biopharma Completes Enrollment in All Three Phase 3 Clinical Studies of Revefenacin (TD-4208) for Treatment of Chronic Obstructive Pulmonary Disease (COPD) - [at noodls] - b5087ee1-cc5c-4051-a07a-682b76517e93.pdf June 1, 2016 Top-Line Data Readout From Two Efficacy Trials Expected Late-Q3/Early-Q4 2016; Twelve-Month Safety Trial Targeted for Completion in 2017 DUBLIN, IRELAND ...
04/08/16 07:29 AMCan the Uptrend Continue for Theravance Biopharma (TBPH)? -
03/18/16 06:30 AM7:30 am Theravance Biopharma presents positive preclinical study results for TD-1473 -
03/18/16 06:30 AMTheravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor - [Marketwired] - Theravance Biopharma, Inc. today announced that positive preclinical study results for TD-1473, a novel, potent, orally administered GI-targeted pan-Janus kinase inhibitor, were presented today at the ...
03/16/16 07:52 AMWhy You Shouldn't Bet Against Theravance Biopharma (TBPH) Stock -
03/14/16 11:33 AMTheravance Biopharma, Inc. :TBPH-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/14/16 07:03 AMTHERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities -
03/11/16 04:13 PMTHERAVANCE BIOPHARMA, INC. Files SEC form 10-K, Annual Report -
03/10/16 12:44 PMEdited Transcript of TBPH earnings conference call or presentation 9-Mar-16 10:00pm GMT -
03/09/16 03:33 PMTheravance Bio reports 4Q loss -
03/09/16 03:23 PMTHERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition -
03/09/16 03:15 PMTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results - [Marketwired] - Theravance Biopharma, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2015. Revenue for the fourth quarter and full year of 2015 was $3.9 million and $42.1 ...
03/09/16 06:30 AMTheravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Study of TD-0714, an Inhibitor of Neprilysin (NEP) - [Marketwired] - Theravance Biopharma, Inc. today announced positive results, including positive biomarker data, from its Phase 1 single-ascending dose clinical trial of TD-0714, the lead molecule in the Company's neprilysin ...
03/09/16 06:07 AMQ4 2015 Theravance Biopharma Inc Earnings Release - After Market Close -
03/03/16 03:30 PMTheravance Biopharma to Present at Cowen and Company 36th Annual Health Care Conference - [Marketwired] - Theravance Biopharma, Inc. announced today that Rick E. Winningham, Chairman and Chief Executive Officer, will present a corporate overview at the upcoming Cowen and Company 36th Annual Health Care Conference ...
03/02/16 03:30 PMTheravance Biopharma to Report Fourth Quarter and Full Year 2015 Financial Results on March 9, 2016 - [Marketwired] - Theravance Biopharma, Inc. today announced that it will release financial results for the period ended December 31, 2015 after market close on Wednesday, March 9, 2016.
03/01/16 07:31 AMTheravance Biopharma, Inc. breached its 50 day moving average in a Bearish Manner : TBPH-US : March 1, 2016 -
02/28/16 01:11 PMTheravance Biopharma, Inc. (TBPH) - 11-Jan-16 THERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur 12-Nov-15 THERAVANCE BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report 10-Nov-15 THERAVANCE BIOPHARMA, INC. Files SEC form 8 ...
02/25/16 03:26 PMTHERAVANCE BIOPHARMA, INC. Files SEC form 8-K, Other Events -
02/18/16 11:51 AMThe Big Short’s Michael Burry Reveals His Top Stock Picks -
02/18/16 07:43 AMTheravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : February 18, 2016 -
02/15/16 09:28 AMBillionaire Seth Klarman’s Top Biotech Stock Picks -
02/13/16 06:33 PMTracking Seth Klarman's Baupost Group Holdings - Q4 2015 Update - Stake Disposals: Alcoa Inc. (NYSE:AA): AA was a very large (third-largest ... Note: Klarman's ownership interest in SunEdison Semiconductor is 19.95%. Theravance Biopharma (NASDAQ:TBPH): TBPH is a 1.91% of the US long portfolio position established ...
02/11/16 09:41 AMNo joke: Opioid constipation drugs are serious business -
02/10/16 07:05 AMTheravance Biopharma Achieves 50% Enrollment in All Three Phase 3 Clinical Studies of Revefenacin (TD-4208) for Treatment of Chronic Obstructive Pulmonary Disease (COPD) - [Marketwired] - Theravance Biopharma, Inc. today announced that 50% enrollment has been surpassed in each of the three ongoing clinical trials comprising the Company's Phase 3 program for revefenacin , an investigational ...
02/04/16 12:48 PMTheravance Biopharma, Inc. – Value Analysis (NASDAQ:TBPH) : February 4, 2016 -
02/04/16 07:09 AMTheravance Biopharma, Inc. breached its 50 day moving average in a Bullish Manner : February 4, 2016 -
02/03/16 03:30 PMTheravance Biopharma to Present at the Leerink Global Healthcare Conference - [Marketwired] - Theravance Biopharma, Inc. announced today that Brett Haumann, Senior Vice President, Clinical Development is scheduled to present at the 2016 Leerink Global Healthcare Conference on Thursday, February ...
01/28/16 06:01 PMCommit To Buy Theravance Biopharma At $12.50, Earn 14.5% Annualized Using Options - Investors considering a purchase of Theravance Biopharma, Inc. (TBPH) stock, but cautious about paying the going market price of $16.03/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting ...
01/26/16 05:42 PMTheravance Biopharma Announces Commercial Launch of VIBATIV® (telavancin) in Canada - DUBLIN, IRELAND--(Marketwired - Jan 26, 2016) - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the commercial launch of VIBATIV ® (telavancin) in Canada. VIBATIV is a bactericidal, once-daily antibiotic ...
01/26/16 07:29 AMTheravance Biopharma Announces Commercial Launch of VIBATIV(R) (telavancin) in Canada - [at noodls] - 8d9dd3fd-df4d-49fa-8668-be8e34c5ca1b.pdf January 26, 2016 Continues Global Expansion Strategy for Once-Daily, Dual Mechanism Antibiotic for MRSA Infections DUBLIN, IRELAND -- (Marketwired) -- 01/26/16 ...
12/08/15 12:17 PMTHERAVANCE BIOPHARMA, INC. Financials -
12/08/15 07:27 AMTheravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-0714, an Inhibitor of Neprilysin (NEP) - [at noodls] - 05120f5b-e7ad-43a2-836a-a9f1e213176a.pdf December 8, 2015 First Clinical Study for Compound From Company's Potential Best-in-Class NEP Inhibitor Development Program; Compound Designed for Broad Use in ...

Social

About Theravance Biopharma

Theravance Biopharma logoTheravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TBPH
  • CUSIP:
Key Metrics:
  • Previous Close: $24.37
  • 50 Day Moving Average: $23.00
  • 200 Day Moving Average: $19.81
  • P/E Ratio: N/A
  • P/E Growth: -0.02
  • Market Cap: $1.21B
  • Beta: 2.25
  • Current Year EPS Consensus Estimate: $-4.27 EPS
  • Next Year EPS Consensus Estimate: $-4.01 EPS
Additional Links:
Theravance Biopharma (NASDAQ:TBPH) Chart for Saturday, July, 30, 2016